Corbus Pharmaceuticals Holdings Inc. $CRBP is expected to show results from its phase 2 systemic sclerosis study on Wednesday.It is a clinical-stage pharmaceutical company, focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases.